Markets
IPO

US IPO Weekly Recap: 2 US IPOs feature first Chinese tech offering of 2015

A generic image of a person touching a tablet.
Credit: Shutterstock photo

Just two small and delayed IPOs - a Chinese e-commerce company and a biotech - raised $105 million this week as management typically avoids investor roadshows before Easter.

The real action in the IPO market came from names like Party City ( PRTY ), Virtu Financial ( VIRT ) and Aduro Biotech ( ADRO ), which joined Etsy ( ETSY ) on next week's IPO calendar . Meanwhile, high-growth chicken and biscuits chain Bojangles (BOJA) submitted an initial filing. Cancer immunotherapy biotech Adaptimmune Therapeutics (ADAP) and muscular dystrophy biotech aTyr Pharma (LIFE) were also added to the pipeline.

WoWo (WOWO) went public as the year's fifth US tech IPO and the first from China when it raised $40 million, the minimum its shareholders mandated. Once known as the "Groupon of China," the online mall (55tuan.com) had been scheduled for over a month but finally achieved its NASDAQ listing and ended the week up 6% on low trading volume. With less than $1 million in cash and $40 million in accrued expenses and accounts payable as of September 30, 2014, the IPO provided much-needed liquidity.

Carbylan Therapeutics (CBYL) had originally been scheduled in January, but it postponed the offering. This week, the osteoarthritis knee pain biotech came back with a lower share price and a higher share count, dropping the proposed market cap by over 40%. By the time it priced, Carbylan raised an additional $5 million and insiders bought one fifth of the deal. Driven by Spark (ONCE), 2015 biotechs average a gain of 24% from their offer price, even as half have fallen negative.

ViewRay postpones

ViewRay (VRAY) became the seventh medical products/diagnostics company to postpone its IPO this year. The MRI systems maker was unable to find investors to commit $13 per share, even though it raised capital at $17 per share in January/February. The IPO market continues to serve as a valuation reality check for private companies.

IPO pricings (week of April 6, 2015)
Company (Ticker) Business Deal Size ($mm) IPO Price vs. Midpoint 1st-day Pop Return as of 4/10
WoWo (WOWO) Chinese online mall $40 0% 3% 6%
Carbylan Therapeutics (CBYL) Biotech: Osteoarthritis pain $65 -62% 11% 6%
Find out why institutional investors rely on Renaissance Capital's Pre-IPO Research for IPOs.

Follow us on Twitter ( @IPOtweet ) for IPO news as it happens and register for our updates on the IPO market.

IPO market snapshot

The Renaissance IPO Index, a market cap weighted basket of newly public companies that is designed to represent the US IPO market, has traded up over 9% year-to-date, compared to 2% for the S&P 500. This suggests that the IPO market remains open to new issuance, which was also supported by the flurry of new filings. Renaissance Capital's IPO ETF ( IPO ) tracks the index, and top ETF holdings include Twitter ( TWTR ), Alibaba (BABA), Hilton (HLT), Ally Financial (ALLY) and Voya Financial (VOYA). To find out if this is the best ETF for you, visit our IPO investing page. The article US IPO Weekly Recap: 2 US IPOs feature first Chinese tech offering of 2015 originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

IPO PRTY ETSY KDNY VIRT

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More